An interventional study of N1 Implant and R1 Robot in Tetraplegia/Tetraparesis, Quadriplegia and Quadriplegia/Tetraplegia, sponsored by Neuralink Corp. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Neuralink Corp · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Quadriplegia with a site in Canada — 5 open to participants now, 7 under way, 1 of them phase 3. Quadriplegia · Canada.
Among the 19 studies in Quadriplegia with a site in Canada, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 16th registered.
224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.
Browse Quadriplegia studies →5 of the 19 studies in Quadriplegia with a site in Canada are open now. Recruiting first, the newest first:
NervGen Pharma · Sites in Canada, United States
Ages 18–75
Washington University School of Medicine · Sites in Canada, United States
Ages 18–80
Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal · Sites in Canada
Ages 16+
University of British Columbia · Sites in Canada
Ages 19+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 57 Quadriplegia studies recruiting now, 17 (30%) set no upper age limit and 28 (49%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 6 is below the median of 15 across 195 interventional studies indexed under Quadriplegia.
Median enrollment 25 across the 15 interventional studies, 35 across the 4 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
Neuralink Corp is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Neuralink Corp has 7 studies filed under Quadriplegia — fewer than ten, so there is no comparison to draw.
3 of the studies in Quadriplegia with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07799532Phase 3NervGen PharmaA Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury | 2027-07 |
| NCT05638191University of British ColumbiaNerve Transfer Surgery to Restore Upper-limb Function After Cervical Spinal Cord Injury | 2027-04 |
| NCT06700304Neuralink CorpCAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Quadriplegia with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia). The N1 Implant is a small, wireless device placed in the skull. It connects to tiny threads inserted into the brain by the R1 Robot, which is a machine designed to carefully place these threads. This study will help researchers learn how well the implant and robot work and if they are safe for use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label
Device: N1 Implant · Device: R1 Robot
The N1 Implant is a type of implantable brain-computer interface.
The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
The Rate of Device-Related Adverse Events (AE)
Time frame: 12 months post-implant
The Rate of Procedure-Related Adverse Events (AE)
Time frame: 12 months post-implant
The Rate of Device-Related Adverse Events (AE)
Time frame: Up to 36 months post-implant
The Rate of Procedure-Related Adverse Events (AE)
Time frame: Up to 36 months post-implant
Change in Montreal Cognitive Assessment (MoCA) score during the Primary Study
Time frame: From baseline to 3-, 6-, 9-, and 12-months post-implantation
Change in Montreal Cognitive Assessment (MoCA) score during the Long-term Follow-up Phase
Time frame: From baseline to 36-months post-implantation
Change in Patient Health Questionnaire-9 (PHQ-9) score during the Primary Study
Time frame: From baseline to 3-, 6-, 9-, and 12-months post-implantation
Change in Patient Health Questionnaire-9 (PHQ-9) score during the Long-term Follow-up Phase
Time frame: From baseline to 36-months post-implantation
Change in Generalized Anxiety Disorder-7 (GAD-7) score during the Primary Study
Time frame: From baseline to 3-, 6-, 9-, and 12-months post-implantation
Change in Generalized Anxiety Disorder-7 (GAD-7) score during the Long-term Follow-up Phase
Time frame: From baseline to 36-months post-implantation
Plan to share: No
Started Nov 2024 (actual). Primary completion is estimated for Nov 2027, 36 months after the start.
Of 97 interventional studies with no phase under Quadriplegia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neuralink Corp